Medication adherence in patients with ocular hypertension or glaucoma

References

• Brody JE The cost of not taking your medicine. New York Times. April 18; D7.
   Google Scholar
• Statistics: Patient Compliance and Medication Adherence. [cited 2017 Oct 30]. Available from: https://www.epill.com/statistics.html
   Google Scholar
• Iuga AO, McGuire MJ. Adherence and health care costs. Risk Manag Healthc Policy. 2014;7:35–44.
   PubMedGoogle Scholar
• Benjamin RM. Medication adherence: helping patients take their medicines as directed. 2012;127:2–3.
   Google Scholar
• Brown MT, Bussell JK. Medication adherence: WHO cares?. Mayo Clin Proc. 2011;86:304–314.
   PubMed Web of Science ®Google Scholar
• Muir KW, Lee PP. Glaucoma medication adherence: room for improvement in both performance and measurement. Arch Ophthalmol. 2011;129:243–245.
   PubMedGoogle Scholar
• World Health Organization. Adherence to long-term therapies: evidence for action. Geneva, Switzerland: World Health Organization. 2003. ISBN 92 4 154599 2.
   Google Scholar
• Zullig LL, Bosworth H. Engaging patients to optimize medication adherence. NEJM Catal. 2017. Available from: https://catalyst.nejm.org/optimize-patients-medication-adherence/.
   Google Scholar
• Vitolins MZ, Rand CS, Rapp SR, et al. Measuring adherence to behavioral and medical interventions. Control Clin Trials. 2000;21:188S–194S.
   PubMedGoogle Scholar
• Robin AL, Novack GD, Covert DW, et al. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol. 2007;144:533–540.
   PubMed Web of Science ®Google Scholar
• Puts MT, Tu HA, Tourangeau A, et al. Factors influencing adherence to cancer treatment in older adults with cancer: a systematic review. Ann Oncol. 2014;25:564–577.
   PubMed Web of Science ®Google Scholar
• Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27:1218–1224.
   PubMed Web of Science ®Google Scholar
• Abegaz TM, Shehab A, Gebreyohannes EA, et al. Nonadherence to antihypertensive drugs: A systematic review and meta-analysis. Medicine (Baltimore). 2017;96:e5641.
   PubMed Web of Science ®Google Scholar
• Buller AJ, Connell B, Spencer AF. Compliance: clear communication’s critical. Br J Ophthalmol. 2005;89:1370.
   PubMed Web of Science ®Google Scholar
• Thier SL, Yu-Isenberg KS, Leas BF, et al. In chronic disease, nationwide data show poor adherence by patients to medication and by physicians to guidelines. Manag Care. 2008;17:48–52, 55–47.
   PubMedGoogle Scholar
• Steiner JF, Koepsell TD, Fihn SD, et al. A general method of compliance assessment using centralized pharmacy records. Description and Validation Med Care. 1988;26:814–823.
   PubMed Web of Science ®Google Scholar
• Calip GS, Elmore JG, Boudreau DM. Characteristics associated with nonadherence to medications for hypertension, diabetes, and dyslipidemia among breast cancer survivors. Breast Cancer Res Treat. 2017;161:161–172.
   PubMed Web of Science ®Google Scholar
• Volpp KG, Troxel AB, Mehta SJ, et al. Effect of electronic reminders, financial incentives, and social support on outcomes after myocardial infarction: the HeartStrong randomized clinical trial. JAMA Intern Med. 2017;177:1093–1101.
   PubMed Web of Science ®Google Scholar
• Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121:2081–2090.
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet. 2004;363:1711–1720.
   PubMed Web of Science ®Google Scholar
• Pascolini D, Mariotti SP. Global estimates of visual impairment: 2010. Br J Ophthalmol. 2012;96:614–618.
   PubMed Web of Science ®Google Scholar
• Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262–267.
   PubMed Web of Science ®Google Scholar
• Bourne RR, Jonas JB, Flaxman SR, et al. Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe: 1990–2010. Br J Ophthalmol. 2014;98:629–638.
   PubMed Web of Science ®Google Scholar
• Flaxman SR, Bourne RRA, Resnikoff S, et al. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. Lancet Glob Health. 2017;5:e1221–e1234.
   PubMed Web of Science ®Google Scholar
• Fingeret M Optometric clinical practice guideline care of the patient with open angle glaucoma. [cited 2013 Nov 5]. Available from: http://www.aoa.org/documents/CPG-9.pdf
   Google Scholar
• Sommer A, Tielsch JM, Katz J, et al. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch Ophthalmol. 1991;109:1090–1095.
   PubMed Web of Science ®Google Scholar
• International Council of Ophthalmology. International council of ophthalmology guidelines for glaucoma eye care. [cited 2018 Feb 5]. Available from: http://www.icoph.org/downloads/ICOGlaucomaGuidelines.pdf
   Google Scholar
• The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. Glaucoma Laser Trial Research Group. Am J Ophthalmol. 1995;120:718–731.
   PubMed Web of Science ®Google Scholar
• Slota C, Sayner R, Vitko M, et al. Glaucoma patient expression of medication problems and nonadherence. Optom Vis Sci. 2015;92:537–543.
   PubMed Web of Science ®Google Scholar
• Robin A, Grover DS. Compliance and adherence in glaucoma management. Indian J Ophthalmol. 2011;59:S93–96.
   PubMed Web of Science ®Google Scholar
• Lee PP, Walt JG, Doyle JJ, et al. A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma. Arch Ophthalmol. 2006;124:12–19.
   PubMed Web of Science ®Google Scholar
• Rossi GC, Pasinetti GM, Scudeller L, et al. Do adherence rates and glaucomatous visual field progression correlate?. Eur J Ophthalmol. 2011;21:410–414.
   PubMed Web of Science ®Google Scholar
• Varma R, Lee PP, Goldberg I, et al. An assessment of the health and economic burdens of glaucoma. Am J Ophthalmol. 2011;152:515–522.
   PubMed Web of Science ®Google Scholar
• Friedman DS, Nordstrom B, Mozaffari E, et al. Glaucoma management among individuals enrolled in a single comprehensive insurance plan. Ophthalmology. 2005;112:1500–1504.
   PubMed Web of Science ®Google Scholar
• Friedman DS, Quigley HA, Gelb L. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Group (GAPS). Invest Ophthalmol Vis Sci. 2007;48:5052–5057.
   PubMed Web of Science ®Google Scholar
• Kass MA, Gordon M, Morley RE Jr., et al. Compliance with topical timolol treatment. Am J Ophthalmol. 1987;103:188–193.
   PubMed Web of Science ®Google Scholar
• Kass MA, Meltzer DW, Gordon M, et al. Compliance with topical pilocarpine treatment. Am J Ophthalmol. 1986;101:515–523.
   PubMed Web of Science ®Google Scholar
• Newman-Casey PA, Robin AL, Blachley T, et al. The most common barriers to glaucoma medication adherence: a cross-sectional survey. Ophthalmology. 2015;122:1308–1316.
   PubMed Web of Science ®Google Scholar
• Gupta R, Patil B, Shah BM, et al. Evaluating eye drop instillation technique in glaucoma patients. J Glaucoma. 2012;21:189–192.
   PubMed Web of Science ®Google Scholar
• Hermann MM, Bron AM, Creuzot-Garcher CP, et al. Measurement of adherence to brimonidine therapy for glaucoma using electronic monitoring. J Glaucoma. 2011;20:502–508.
   PubMed Web of Science ®Google Scholar
• Kholdebarin R, Campbell RJ, Jin YP, et al. Multicenter study of compliance and drop administration in glaucoma. Can J Ophthalmol. 2008;43:454–461.
   PubMed Web of Science ®Google Scholar
• O’Hare F, Jeganathan VS, Rokahr CG, et al. Readability of prescription labels and medication recall in a population of tertiary referral glaucoma patients. Clin Exp Ophthalmol. 2009;37:849–854.
   PubMed Web of Science ®Google Scholar
• Tsai JC, McClure CA, Ramos SE, et al. Compliance barriers in glaucoma: a systematic classification. J Glaucoma. 2003;12:393–398.
   PubMed Web of Science ®Google Scholar
• Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11:44–47.
   PubMed Web of Science ®Google Scholar
• Vrijens B, Vincze G, Kristanto P, et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336:1114–1117.
   PubMed Web of Science ®Google Scholar
• Reardon G, Kotak S, Schwartz GF. Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review. Patient Prefer Adherence. 2011;5:441–463.
   PubMed Web of Science ®Google Scholar
• Skalicky SE, Goldberg I. Adherence and persistence: the challenges for glaucoma medical therapy. Asia Pac J Ophthalmol (Phila). 2013;2:356–361.
   PubMedGoogle Scholar
• Schwartz GF, Quigley HA. Adherence and persistence with glaucoma therapy. Surv Ophthalmol. 2008;53:S57–68.
   PubMed Web of Science ®Google Scholar
• Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment: clinical applications. JAMA. 2002;288:2880–2883.
   PubMed Web of Science ®Google Scholar
• Schwartz GF Enhancing glaucoma patients’ adherence to prescribed medical therapy. [ cited 2018 Feb 5]. Available from: http://glaucomatoday.com/pdfs/gt0714_F_schwartz.pdf
   Google Scholar
• Okeke CO, Quigley HA, Jampel HD, et al. Adherence with topical glaucoma medication monitored electronically: the Travatan Dosing Aid study. Ophthalmology. 2009;116:191–199.
   PubMed Web of Science ®Google Scholar
• Gatwood JD, Johnson J, Jerkins B. Comparisons of self-reported glaucoma medication adherence with a new wireless device: a pilot study. J Glaucoma. 2017;26:1056–1061.
   PubMed Web of Science ®Google Scholar
• Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg. 1995;26:233–236.
   PubMedGoogle Scholar
• Hermann MM, Diestelhorst M. Microprocessor controlled compliance monitor for eye drop medication. Br J Ophthalmol. 2006;90:830–832.
   PubMed Web of Science ®Google Scholar
• Sayner R, Carpenter DM, Blalock SJ, et al. Accuracy of patient-reported adherence to glaucoma medications on a visual analog scale compared with electronic monitors. Clin Ther. 2015;37:1975–1985.
   PubMed Web of Science ®Google Scholar
• Boland MV, Chang DS, Frazier T, et al. Automated telecommunication-based reminders and adherence with once-daily glaucoma medication dosing: the automated dosing reminder study. JAMA Ophthalmol. 2014;132:845–850.
   PubMed Web of Science ®Google Scholar
• Covert D, Robin AL, Novack GD. Systemic medications and glaucoma patients. Ophthalmology. 2005;112:1849.
   PubMed Web of Science ®Google Scholar
• Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy?. Ophthalmology. 2005;112:863–868.
   PubMed Web of Science ®Google Scholar
• Denis P. Adverse effects, adherence and cost-benefits in glaucoma treatment. Eur Ophthalmic Rev. 2011;5:116–122.
   Google Scholar
• Djafari F, Lesk MR, Harasymowycz PJ, et al. Determinants of adherence to glaucoma medical therapy in a long-term patient population. J Glaucoma. 2009;18:238–243.
   PubMed Web of Science ®Google Scholar
• Sleath B, Robin AL, Covert D, et al. Patient-reported behavior and problems in using glaucoma medications. Ophthalmology. 2006;113:431–436.
   PubMed Web of Science ®Google Scholar
• Friedman DS, Okeke CO, Jampel HD, et al. Risk factors for poor adherence to eyedrops in electronically monitored patients with glaucoma. Ophthalmology. 2009;116:1097–1105.
   PubMed Web of Science ®Google Scholar
• Sleath B, Blalock SJ, Carpenter DM, et al. Ophthalmologist-patient communication, self-efficacy, and glaucoma medication adherence. Ophthalmology. 2015;122:748–754.
   PubMed Web of Science ®Google Scholar
• Freedman RB, Jones SK, Lin A, et al. Influence of parental health literacy and dosing responsibility on pediatric glaucoma medication adherence. Arch Ophthalmol. 2012;130:306–311.
   PubMedGoogle Scholar
• Winfield AJ, Jessiman D, Williams A, et al. A study of the causes of non-compliance by patients prescribed eyedrops. Br J Ophthalmol. 1990;74:477–480.
   PubMed Web of Science ®Google Scholar
• Sleath BL, Krishnadas R, Cho M, et al. Patient-reported barriers to glaucoma medication access, use, and adherence in southern India. Indian J Ophthalmol. 2009;57:63–68.
   PubMed Web of Science ®Google Scholar
• Sleath B, Ballinger R, Covert D, et al. Self-reported prevalence and factors associated with nonadherence with glaucoma medications in veteran outpatients. Am J Geriatr Pharmacother. 2009;7:67–73.
   PubMed Web of Science ®Google Scholar
• Lacey J, Cate H, Broadway DC. Barriers to adherence with glaucoma medications: a qualitative research study. Eye (Lond). 2009;23:924–932.
   PubMed Web of Science ®Google Scholar
• Olthoff CM, Hoevenaars JG, van Den Borne BW, et al. Prevalence and determinants of non-adherence to topical hypotensive treatment in Dutch glaucoma patients. Graefes Arch Clin Exp Ophthalmol. 2009;247:235–243.
   PubMed Web of Science ®Google Scholar
• Stone JL, Robin AL, Novack GD, et al. An objective evaluation of eyedrop instillation in patients with glaucoma. Arch Ophthalmol. 2009;127:732–736.
   PubMed Web of Science ®Google Scholar
• Hennessy AL, Katz J, Covert D, et al. A video study of drop instillation in both glaucoma and retina patients with visual impairment. Am J Ophthalmol. 2011;152:982–988.
   PubMed Web of Science ®Google Scholar
• Schwartz GF, Hollander DA, Williams JM. Evaluation of eye drop administration technique in patients with glaucoma or ocular hypertension. Curr Med Res Opin. 2013;29:1515–1522.
   PubMed Web of Science ®Google Scholar
• Aptel F, Masset H, Burillon C, et al. The influence of disease severity on quality of eye-drop administration in patients with glaucoma or ocular hypertension. Br J Ophthalmol. 2009;93:700–701.
   PubMed Web of Science ®Google Scholar
• Sleath B, Blalock S, Covert D, et al. The relationship between glaucoma medication adherence, eye drop technique, and visual field defect severity. Ophthalmology. 2011;118:2398–2402.
   PubMed Web of Science ®Google Scholar
• Tamrat L, Gessesse GW, Gelaw Y. Adherence to topical glaucoma medications in Ethiopian patients. Middle East Afr J Ophthalmol. 2015;22:59–63.
   PubMed Web of Science ®Google Scholar
• Friedman DS, Hahn SR, Gelb L, et al. Doctor-patient communication, health-related beliefs, and adherence in glaucoma results from the Glaucoma Adherence and Persistency Study. Ophthalmology. 2008;115:1320–1327.
   PubMed Web of Science ®Google Scholar
• Stryker JE, Beck AD, Primo SA, et al. An exploratory study of factors influencing glaucoma treatment adherence. J Glaucoma. 2010;19:66–72.
   PubMed Web of Science ®Google Scholar
• Lunnela J, Kaariainen M, Kyngas H. The views of compliant glaucoma patients on counselling and social support. Scand J Caring Sci. 2010;24:490–498.
   PubMed Web of Science ®Google Scholar
• Budenz DL. A clinician’s guide to the assessment and management of nonadherence in glaucoma. Ophthalmology. 2009;116:S43–47.
   PubMed Web of Science ®Google Scholar
• Barnebey HS, Robin AL. Adherence to fixed-combination versus unfixed travoprost 0.004%/timolol 0.5% for glaucoma or ocular hypertension: a randomized trial. Am J Ophthalmol. 2017;176:61–69.
   PubMed Web of Science ®Google Scholar
• Schwartz G, Burk C, Bennett T, et al. Adherence and persistence with glaucoma therapy: brimonidine/timolol versus dorzolamide/timolol and various two-bottle combinations. J Clin Exp Ophthalmol. 2012;3:1–6.
   Google Scholar
• Higginbotham EJ, Hansen J, Davis EJ, et al. Glaucoma medication persistence with a fixed combination versus multiple bottles. Curr Med Res Opin. 2009;25:2543–2547.
   PubMed Web of Science ®Google Scholar
• Schehlein EM, Novack GD, Robin AL. New classes of glaucoma medications. Curr Opin Ophthalmol. 2017;28:161–168.
   PubMed Web of Science ®Google Scholar
• Perera SA, Ting DS, Nongpiur ME, et al. Feasibility study of sustained-release travoprost punctum plug for intraocular pressure reduction in an Asian population. Clin Ophthalmol. 2016;10:757–764.
   PubMed Web of Science ®Google Scholar
• Envisia Therapeutics releases interim ENV515 (travoprost XR) phase 2 data demonstrating 11-month duration-of-action after a single dose in patients with glaucoma. [ cited 2018 Feb 5]. Available from: http://www.envisiatherapeutics.com/envisia-therapeutics-releases-interim-env515-travoprost-xr-phase-2-data-demonstrating-11-month-duration-of-action-after-a-single-dose-in-patients-with-glaucoma/
   Google Scholar
• Willard-Grace R, Chen EH, Hessler D, et al. Health coaching by medical assistants to improve control of diabetes, hypertension, and hyperlipidemia in low-income patients: a randomized controlled trial. Ann Fam Med. 2015;13:130–138.
   PubMed Web of Science ®Google Scholar
• Aikens JE, Trivedi R, Aron DC, et al. Integrating support persons into diabetes telemonitoring to improve self-management and medication adherence. J Gen Intern Med. 2015;30:319–326.
   PubMed Web of Science ®Google Scholar
• Abughosh SM, Wang X, Serna O, et al. A pharmacist telephone intervention to identify adherence barriers and improve adherence among nonadherent patients with comorbid hypertension and diabetes in a Medicare Advantage plan. J Manag Care Spec Pharm. 2016;22:63–73.
   PubMed Web of Science ®Google Scholar
• Newman-Casey PA, Weizer JS, Heisler M, et al. Systematic review of educational interventions to improve glaucoma medication adherence. Semin Ophthalmol. 2013;28:191–201.
   PubMed Web of Science ®Google Scholar
• Sleath B, Carpenter DM, Blalock SJ, et al. Applying the resources and supports in self-management framework to examine ophthalmologist-patient communication and glaucoma medication adherence. Health Educ Res. 2015;30:693–705.
   PubMed Web of Science ®Google Scholar
• Feng A, O’Neill J, Holt M, et al. Success of patient training in improving proficiency of eyedrop administration among various ophthalmic patient populations. Clin Ophthalmol. 2016;10:1505–1511.
   PubMed Web of Science ®Google Scholar
• Taylor SA, Galbraith SM, Mills RP. Causes of non-compliance with drug regimens in glaucoma patients: a qualitative study. J Ocul Pharmacol Ther. 2002;18:401–409.
   PubMed Web of Science ®Google Scholar
• Christie D, Channon S. The potential for motivational interviewing to improve outcomes in the management of diabetes and obesity in paediatric and adult populations: a clinical review. Diabetes Obes Metab. 2014;16:381–387.
   PubMed Web of Science ®Google Scholar
• Powell PW, Hilliard ME, Anderson BJ. Motivational interviewing to promote adherence behaviors in pediatric type 1 diabetes. Curr Diab Rep. 2014;14:531.
   PubMed Web of Science ®Google Scholar
• DiIorio C, McCarty F, Resnicow K, et al. Using motivational interviewing to promote adherence to antiretroviral medications: a randomized controlled study. AIDS Care. 2008;20:273–283.
   PubMed Web of Science ®Google Scholar
• Zomahoun HTV, Guenette L, Gregoire JP, et al. Effectiveness of motivational interviewing interventions on medication adherence in adults with chronic diseases: a systematic review and meta-analysis. Int J Epidemiol. 2017;46:589–602.
   PubMed Web of Science ®Google Scholar
• Lundahl B, Burke BL. The effectiveness and applicability of motivational interviewing: a practice-friendly review of four meta-analyses. J Clin Psychol. 2009;65:1232–1245.
   PubMed Web of Science ®Google Scholar
• Sleath B, Blalock SJ, Carpenter DM, et al. Provider education about glaucoma and glaucoma medications during videotaped medical visits. J Ophthalmol. 2014;2014:238939.
   PubMedGoogle Scholar
• Hahn SR, Friedman DS, Quigley HA, et al. Effect of patient-centered communication training on discussion and detection of nonadherence in glaucoma. Ophthalmology. 2010;117:1339–1347 e1336.
   PubMed Web of Science ®Google Scholar